ReviewJournal of cellular and molecular medicine
Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.
Review in Journal of cellular and molecular medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Association between cyclooxygenase-2 (COX-2) 8473 T > C polymorphism and cancer risk: a meta-analysis and trial sequential analysis.BMC cancer · 2018Pooled it
- Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis.BMJ open · 2015Pooled it
- Cyclooxygenase-2 polymorphisms and susceptibility to colorectal cancer: a meta-analysis.Yonsei medical journal · 2013Pooled it
- Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.Cancer immunity · 2008Trial
- Dietary risk factors for lung cancer: an umbrella review of systematic review and meta-analysis.Translational cancer research · 2026Review
- Celecoxib in oncology: targeting the COX-2/PGEFrontiers in pharmacology · 2025Review
- Identification of Novel Kinase-Transcription Factor-mRNA-miRNA Regulatory Network in Nasopharyngeal Carcinoma by Bioinformatics Analysis.International journal of general medicine · 2021Article
- PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation.International journal of molecular sciences · 2020Article
- Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032.Oncogene · 2020Article
- Single Nucleotide Variants Associated with Colorectal Cancer Among Iranian Patients: A Narrative Review.Pharmacogenomics and personalized medicine · 2020Review
- Pyruvate Kinase M2 Promotes Prostate Cancer Metastasis Through Regulating ERK1/2-COX-2 Signaling.Frontiers in oncology · 2020Article
- Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma.Frontiers in pharmacology · 2019Article
- Article
- Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas.Oncology letters · 2017Article
- Dual effects of acetylsalicylic acid on ERK signaling and Mitf transcription lead to inhibition of melanogenesis.Molecular and cellular biochemistry · 2016Article
- Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.Free radical biology & medicine · 2015Article
- Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities.Journal of translational medicine · 2015Article
- Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients.BMC cancer · 2014Article
- Article
- COX-2 overexpression increases malignant potential of human glioma cells through Id1.Oncotarget · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclooxygenase (COX)-2 and the prostaglandins resulting from its enzymatic activity have been shown to play a role in modulating cell growth and development of human neoplasia. Evidence includes a direct relationship between COX-2 expression and cancer incidence in humans and animal models, increased tumorigenesis after genetic manipulation of COX-2, and significant anti-tumor properties of non-steroidal anti-inflammatory drugs in animal models and in some human cancers. Recent data showed that COX-2 and the derived prostaglandins are involved in control of cellular growth, apoptosis, and signal through a group of nuclear receptors named peroxisome proliferator-activated receptors (PPARs). In this article we will review some of the findings suggesting that COX-2 is involved in multiple cellular mechanisms that lead to tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.